Navigation Links
Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
Date:4/15/2008

ROCHESTER, Minn., April 15, 2008 /PRNewswire-USNewswire/ -- A new Mayo Clinic study found that young-onset dementia often is caused by neurodegenerative or autoimmune/inflammatory conditions, but only rarely by Alzheimer's disease. This differs substantially from the common causes of dementia in older individuals (Alzheimer's disease and other neurodegenerative dementias). These findings will be presented at the American Academy of Neurology Annual Meeting in Chicago on April 15.

Dementia represents a progressive decline in a person's cognitive function that affects the ability to think, speak, reason, remember and move. The most common forms of dementia are Alzheimer's disease, vascular dementia and Lewy body dementia. Approximately 12 in 100,000 people may develop dementia prior to age 45, called young-onset dementia.

"After seeing several patients in their 20s who had graduated from college and were suddenly experiencing severe dementia, I wanted to try to provide answers as to what was causing dementia at such young ages," says Brendan Kelley, M.D., an author of this study and a neurologist at Mayo Clinic.

Dr. Kelley and a team of Mayo Clinic physicians set out to identify the characteristics and causes of dementia prior to age 45. They identified 235 individuals, ages 17 to 45, who previously had normal cognitive function and were evaluated for progressive cognitive decline at Mayo Clinic from 1996 to 2006. In one-third of patients, the dementia was caused by a neurodegenerative disorder such as frontotemporal dementia, Huntington's disease or familial prion disease. However, Alzheimer's disease was an uncommon cause. In 20 percent of patients, young-onset dementia was caused by autoimmune or inflammatory conditions such as multiple sclerosis, autoimmune encephalopathy or neuropsychiatric lupus. According to Dr. Kelley, this is an important finding, because many of these diseases may have specific treatments.

Additionally, 10 percent had metabolic disorders commonly thought to occur mainly in children. In 19 percent of the patients, the cause of young-onset dementia remained unknown despite thorough and exhaustive evaluation.

"This study sheds light on the fact that young people do, in fact, develop dementia, and that there are important differences between the causes of young-onset dementia and the causes of dementia in older individuals," says Dr. Kelley. "However, more research is required to better understand the characteristics and most effective treatments for young patients with dementia."

Brad Bishop is one of the patients who influenced Dr. Kelley to pursue this research. Bishop, age 27, was diagnosed with frontotemporal dementia in 2006. According to his parents, he was an energetic, thoughtful, caring and intelligent young man who graduated from college in 2004 with a double major in business and computers. His symptoms of dementia started around age 21, including withdrawal from people outside his family, inappropriate behavior, poor financial judgment and progressive decline in cognitive function. Now, Bishop needs around-the-clock care as his brain continues to deteriorate.

"We are seeing our son disappear before our eyes, little bit by little bit," says Susan Bishop, his mother. "We'll always hope for a miracle, but realistically we just want Brad to be safe, happy, comfortable and treated with the dignity and respect that he deserves...every day we have with him is a gift."

Dr. Kelley and his team will continue to learn more by prospectively following patients like Bishop to better understand what causes early-onset dementia. Other members of the Mayo Clinic research team included Bradley Boeve, M.D., and Keith Josephs, M.D.

To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com) is available as a resource for your health stories.


'/>"/>
SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
4. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
5. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
6. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
7. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
8. Presentation of HeartWare Clinical Results
9. Clinically Proven Treatment Offers Help to Rosacea Sufferers
10. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
11. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve as ... tenure, Paul has served us in multiple leadership roles since ... in Jun. 2015 and has provided decisive, strategic leadership which ...
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
Breaking Medicine Technology:
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with ... If so, you may be interested in participating in a research study that focuses ... is to understand more about the relational aspects of adults who have gluten sensitivities ...
(Date:8/19/2017)... Rockville, MD (PRWEB) , ... August 18, 2017 ... ... Food and Drug Administration Reauthorization Act of 2017, legislation that provides for greater ... perceived mild to moderate hearing loss to access OTC hearing aids without being ...
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the ... there are two sides. There are not two sides to hatred, bigotry, discrimination, and ... and prejudice, and the NPEIV stands against all forms of such hatred and discrimination ...
(Date:8/18/2017)... ... August 19, 2017 , ... Mr. Noppadon Pakprot, Deputy Governor ... Thailand Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest “Functional ... Tourism Products and Business at TAT said, “Thailand has long been recognized as ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet ... advocating for active, healthy lifestyles and highlighting the importance of proactive eye and ... impairments and shares the latest innovations in hearing aid technology. , In ...
Breaking Medicine News(10 mins):